$1.10
1.85%
Nasdaq, Oct 09, 04:07 pm EDT. Closed.
ISIN
US39959A2050
Symbol
UPXI

Upexi Stock price

$1.10
+0.07 6.28% 1M
+0.06 5.77% 6M
-0.58 34.52% YTD
-5.75 83.94% 1Y
-31.70 96.65% 3Y
-101.30 98.93% 5Y
-110.90 99.02% 10Y
-110.90 99.02% 20Y
Nasdaq, Closing price Fri, Oct 09 2026
+0.02 1.85%
ISIN
US39959A2050
Symbol
UPXI

Is Upexi a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 9,113 stocks worldwide.

Key metrics

Basic
Market capitalization
$97.0m
Enterprise Value
$205.0m
Net debt
$108.0m
Cash
$115.4m
Shares outstanding
78.7m
Valuation
P/E
negative
P/S | estimate
3.9 | 4.2
EV/Sales | estimate
8.2 | 8.8
EV/FCF | ex SBC
negative | negative
P/B
negative
Financial Health
Equity Ratio
-29.9%
Return on Equity
457.3%
ROCE
-190.6%
ROIC
-
Debt/Equity
-4.2
Share-Based Compensation & Dilution
SBC | % of Revenue
$21.9m | 87.6%
SBC as % of FCF
-
SBC Growth 1Y
937.9%
Share Count Growth 1Y
105.6%
Shareholder Yield
-105.6%
Financials
Revenue | estimate
$25.0m | $23.3m
EBITDA
$-207.3m
EBIT
$-207.8m
Net Income
$-246.1m
Free Cash Flow | ex SBC
$-61.8m | $-83.7m
Growth
Revenue | estimate
58.1% | -7.0%
EBITDA
-1,610.5%
EBIT
-1,513.7%
Net Income
-1,698.7%
Free Cash Flow
-601.4%
Margin
Gross
89.5%
EBITDA
-829.3%
EBIT
-831.1%
Net
-984.3%
Free Cash Flow | ex SBC
-247.2% | -334.8%
More
EPS
$-3.4
FCF per Share
$-0.8
Short interest
19.2%
Employees
59
Rev per Employee
$420.0k

Upexi Stock Analysis

Unlock Scores for Free

Analyst Opinions

8 Analysts have issued a Upexi forecast:

7x Buy
88%
1x Hold
13%

Analyst Opinions

8 Analysts have issued a Upexi forecast:

Buy
88%
Hold
13%

Upexi Events

Past Events
SEP
17
Q4 2026 Earnings Call
23 days ago
MAY
12
Q3 2026 Earnings Call
5 months ago
FEB
10
Q2 2026 Earnings Call
8 months ago
NOV
11
Q1 2026 Earnings Call
11 months ago

Financial data from Upexi

Jun '26
+/-
%
25 25
58% 58%
100%
- Direct Costs 2.63 2.63
47% 47%
11%
22 22
106% 106%
89%
- Selling and Administrative Expenses 54 54
134% 134%
215%
- Research and Development Expense - -
-
-
-207 -207
1,610% 1,610%
-829%
- Depreciation and Amortization 0.46 0.46
39% 39%
2%
EBIT (Operating Income) EBIT -208 -208
1,514% 1,514%
-831%
Net Profit -246 -246
1,699% 1,699%
-984%

In millions USD.

Don't miss a Thing! We will send you all news about Upexi directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Upexi Stock News

Neutral
GlobeNewsWire
●
23 days ago
Digital Asset Revenue Totaled $17.4 Million for Fiscal Year 2026 Solana Treasury Totaled Approximately 2.34 Million SOL as of June 30, 2026 Conference Call Scheduled for Today, September 17, 2026, at 5:30 P.M. E.T. TAMPA, Fla.
Neutral
GlobeNewsWire
●
26 days ago
TAMPA, Fla., Sept. 15, 2026 (GLOBE NEWSWIRE) -- Upexi, Inc. (NASDAQ: UPXI) (the “Company” or “Upexi”), a leading Solana-focused digital asset treasury company and consumer brands owner, today announced that it plans to host a conference call and report its financial results for the fiscal year 2026 ended June 30, 2026, on Thursday, September 17, 2026.
More Upexi News

Company Profile

Upexi, Inc. engages in the development, manufacturing, and distribution of consumer products through direct-to-consumer network, wholesale partnerships, and major third-party platforms like Amazon. Its brands include LuckyTail, Prax, Cure Mushrooms, Moonwlkr, and Gumi Labs. The company was founded on September 5, 2018 and is headquartered in Tampa, FL.

Head office United States
CEO Mr. Marshall
Employees 59
Website ir.upexi.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today